Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction

Chaib S, Langhi Prata LGP, Suda M, Sola A, Mitchell TJ, Anastasiadis ZP

1. 01

   PD-L2 is upregulated on senescent human cells and rises with aging

2. 02

   Senolytics preferentially remove high-PD-L2-expressing senescent cells

3. 03

   Aged PD-L2 knockout mice accumulate fewer senescent cells and show better insulin sensitivity and grip strength

4. 04

   Anti-PD-L2 antibody therapy restored insulin sensitivity in aged wild-type mice

5. 05

   Supports soluble PD-L2 as a candidate circulating marker of senescent-cell burden

Study Design

Preclinical mechanistic study

Sample Size

Not reported

Study Duration

Not reported

Methodology

Human senescent cell models, aged wild-type and PD-L2 knockout mice, antibody blockade experiments, plus human correlative measurements of soluble PD-L2

Limitations

Preclinical: intervention data are entirely in mice; human data are correlative (soluble PD-L2 levels), not interventional. Checkpoint blockade carries established autoimmune toxicity risk and has never been trialled for an aging indication. No dosing, safety or efficacy data exist for anti-PD-L2 as a geroprotective therapy in humans.